Auswahl der wissenschaftlichen Literatur zum Thema „CRR2“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "CRR2" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "CRR2"

1

Hashimoto, Mihoko, Tsuyoshi Endo, Gilles Peltier, Masao Tasaka und Toshiharu Shikanai. „A nucleus-encoded factor, CRR2, is essential for the expression of chloroplastndhBinArabidopsis“. Plant Journal 36, Nr. 4 (November 2003): 541–49. http://dx.doi.org/10.1046/j.1365-313x.2003.01900.x.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ruwe, Hannes, Bernard Gutmann, Christian Schmitz‐Linneweber, Ian Small und Peter Kindgren. „The E domain of CRR2 participates in sequence‐specific recognition of RNA in plastids“. New Phytologist 222, Nr. 1 (06.12.2018): 218–29. http://dx.doi.org/10.1111/nph.15578.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Waschbusch, Gerd, Andrea Rolle und Johannes Biewer. „Die Neugestaltung des aufsichtsrechtlichen Handelsbuchs nach dem CRR2-Verordnungsvorschlag im Lichte des IFRS 9“. Zeitschrift für das gesamte Bank- und Börsenwesen 66, Nr. 2 (2018): 103. http://dx.doi.org/10.47782/oeba201802010301.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Hogendorf, Piotr, Anna Suska, Aleksander Skulimowski, Joanna Rut, Monika Grochowska, Aleksandra Wencel, Filip Dziwisz et al. „Neutrophil-lymphocyte ratio and creatinine reduction ratio predict good early graft function among adult cadaveric donor renal transplant recipients. Single institution series“. Polish Journal of Surgery 90, Nr. 2 (30.04.2018): 28–33. http://dx.doi.org/10.5604/01.3001.0011.7499.

Der volle Inhalt der Quelle
Annotation:
Background Delayed graft function (DGF) is a common complication following kidney transplantation and is associated with ischemia-reperfusion injury (IRI). Lymphocytes contribute to the pathogenesis of IRI and ischemia-reperfusion related delayed graft function Materials and Methods 135 Caucasian patients received a kidney graft from deceased heart-beating organ donors. We divided patients into 2 groups- patients with the eGFR>=30 on the 21st day post-transplantation (n=36) and patients with the eGFR<30 on the 21st day post-transplantation (n=99) to assess kidney graft function. We measured the serum creatinine levels on 1st and 2nd post-transplant day and preoperative levels of monocytes, lymphocytes, platelets and neutrophils and their ratios. Results We have found statistically significant differences between the eGFR<30 and the eGFR>=30 groups in the average lnLymphocytes (0,36 +/-0,6 vs -0,016 +/-0,74 respectively p=0,004) lnNLR ( 1,27 +/-0,92 vs. 1,73+/-1,08 p=0,016) lnLMR (1,01 +/-0,57 vs. 0,73 +/-0,64 p=0,02), lnPLR (4,97 +/-0,55 vs. 5,26 +/- 0,67 p=0,023) and CCR2% (-20,20 +/- 21,55 vs. -4,29 +/- 29,62 p=0,004 . On univariate analysis, factors of lnLymphocytes >=0,22 (OR=0,331 95%CI 0,151-0,728 p=0,006), lnLMR>=1,4 (OR=0,255 95%CI 0,072-0,903 p=0,034) were associated with worse graft function while lnNLR>=1,05 (OR=2,653 95%CI 1,158-6,078 p=0,021), lnPLR>=5,15 (OR=2,536 95%CI 1,155-5,566 p=0,02) and CRR2 (OR=3,286 95% CI 1,359-7,944 p=0,008) indicated better graft function Conclusion Higher absolute lymphocyte count (lnLymphocytes) and lnLMR as well as lower lnNLR and lnPLR were associated with lower eGFR on the 21st day after kidney transplantation. On multivariate analysis CRR2 in combination with either lnLymphocytes, lnNLR or lnPLR improved the accuracy of detecting patients with poor graft function.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Hosono, Naoko, Hideki Makishima, Bartlomiej P. Przychodzen, Andres Jerez, Chantana Polprasert, Yuichi Shiraishi, Kenichi Chiba et al. „Whole Exome Sequencing (“mutatome”) Of Deletion 5q“. Blood 122, Nr. 21 (15.11.2013): 656. http://dx.doi.org/10.1182/blood.v122.21.656.656.

Der volle Inhalt der Quelle
Annotation:
Abstract Interstitial deletion of chromosome 5q (del(5q)) is one of the most common karyotypic abnormalities in MDS. While a relatively small fraction of patients with del(5q) and 5q- syndrome show a relatively uniform clinical phenotype and a low rate of progression, the majority of del(5q) myeloid neoplasms are more heterogeneous. Prognosis correlates with the size and location of the deletion, with large deletions spanning subtelomeric and/or subcentromeric region correlating with a poor prognosis. Survival differences may relate to still undefined pathogenetic mechanisms underlying del(5q), which may involve hemizygous mutations or haploinsufficiency. With the latter scenario, it is possible that heterozygous mutations of genes located on 5q may phenocopy the deletion. To further elucidate the molecular mechanisms underlying del(5q), we preformed a comprehensive analysis of myeloid neoplasms using single nucleotide polymorphism array (SNP-A) and next generation whole exome sequencing (NGS) of paired DNA samples (germline/tumor) from 55 cases characterized by del(5q) among a total 428 patients with MDS and related disorders; we focused on mutations located on 5q in both diploid and deletion cases. In the total cohort, we identified 243 somatic mutations in 158 genes on chr5q, including well-known NPM1 or novel recurrent DDX41 mutations; 147 mutations were heterozygous, 11 hemizygous (in del(5q)). No homozygous mutations were found. Applying SNP-A-based karyotyping, we defined the commonly deleted region (CDR) as between 5q32 and 5q33.2 (145299747-153828955). In patients with 5q- syndrome, the proximal and terminal regions of chr5q were always retained; therefore we defined commonly retained regions (CRR) as CRR1 (proximal, 5q11.1 to 5q14.2, 48400001-81634579) and CRR2 (distal, 5q34 to 5q35.3, 164213764-180915260). The deletions of CRRs consequently contributed to worse prognosis in the aggressive types of MDS with longer del(5q). First we focused our study on the genes located on CRRs. We identified 120 heterozygous alterations in CRRs, including CWC27 (5q12.3), MAP1B (n=2, 5q13.2), NPM (n=50, 5q35.1), C5orf25 (n=4, 5q35.2) and DDX41 (n=4, 5q35.3); these mutations occurred only in a heterozygous configuration. Interestingly, spliceosome-associated gene CWC27 and RNA helicase DDX41 showed haploinsufficient expression in haploid cases without mutation, suggesting that mutated genes located on CRRs can be pathogenic due to both haploinsufficiency of WT genes and heterozygous mutations. Furthermore, patients with decreased expression of these genes had a poor survival (CWC27; HR=2.48, DDX41; HR=1.98). In positions corresponding to CDR and its proximal regions, we found 123 heterozygous alterations in 97 genes (50% of all alterations on 5q found), including recurrently mutated genes (FAT2: n=4; G3BP1: n=2) and hemizygous mutations of KDM3B (n=3, 5q31.2) and MCC (n=1, 5q22.2). In GPR98, associated with Usher syndrome, we detected both recurrent heterozygous and hemizygous mutations (each n=1). Also, minor alleles (frequencies were .002 and .004) of non-synonymous variants of GPR98 were selectively retained and wild-type alleles were deleted in del(5q) cases (n=2). We also searched accessory genetic events observed on other chromosomes in del(5q) cases. By SNP-A, deletions of CRRs (longer del(5q)) were significantly more associated with additional chromosomal defects. Similarly, some specific genes, including the splicing machinery genes and IDH family genes, were uniquely observed in the longer del(5q) cohort. In conclusion, we detected multiple pathogenic mutations in whole chr5q which might stratify del(5q) patients at risk for disease progression, though no single mutations could explain a majority of cases. Decreased expression or mutation of CWC27 and DDX41, located on CRRs, may exemplify the common pathophysiology shared by heterozygous mutations and haploinsufficient expressions on chr5q. Consequently, it is possible that deletion alone, through decreased expression, may be pathogenic. Disclosures: Makishima: AA & MDS international foundation: Research Funding; Scott Hamilton CARES grant: Research Funding. Polprasert:MDS foundation: Research Funding. Maciejewski:NIH: Research Funding; Aplastic anemia&MDS International Foundation: Research Funding.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Pfeifer, Lukáš, und Zdeněk Pikhart. „Leverage Ratio and its Potential For Enhancing the Effectiveness of Capital Regulation“. Journal of Central Banking Theory and Practice 8, Nr. 2 (01.05.2019): 129–46. http://dx.doi.org/10.2478/jcbtp-2019-0017.

Der volle Inhalt der Quelle
Annotation:
Abstract The article deals with the procyclical development of risk weights and hence the risk-weighted capital ratio. The leverage ratio should be included in the regulatory reform package (CRR2) as a (non-risk-weighted) prudential backstop. The article defines the complementary relationship of capital and leverage by describing their different responses to the cyclical development associated with the change in the quality of assets in the various phases of the financial cycle. The results of the panel regression on a sample of selected countries illustrate: (i) that the banking sectors with lower capital adequacy relatively more increased the capital ratio in the period of financial stress and more often changed the structure of the assets into less risky assets for the improvement of the capital ratio, with a negative impact on profit; (ii) significantly lower pro-cyclicality of the leverage ratio than the capital ratio.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Cheng, Haiying, Ligang Zhou, Wanling Zhu, Ajin Wang, Chuyan Tang, Owen Chan, Robert S. Sherwin und Rory J. McCrimmon. „Type 1 corticotropin-releasing factor receptors in the ventromedial hypothalamus promote hypoglycemia-induced hormonal counterregulation“. American Journal of Physiology-Endocrinology and Metabolism 293, Nr. 3 (September 2007): E705—E712. http://dx.doi.org/10.1152/ajpendo.00136.2007.

Der volle Inhalt der Quelle
Annotation:
Type 2 corticotropin-releasing factor (CRF) receptors (CRFR2) within the ventromedial hypothalamus (VMH), a key glucose-sensing region, play a major role in regulating the hormonal counterregulatory responses (CRRs) to acute hypoglycemia. The VMH expresses both subtypes of CRF receptors, CRFR1 and CRFR2. The objective of this study was to examine the role of the CRFR1 receptor in the VMH in the regulation of the CRR to acute hypoglycemia. To compare the hormonal CRR to hypoglycemia, awake and unrestrained Sprague-Dawley rats were bilaterally microinjected to the VMH with either 1) aECF, 2) CRF (1 pmol/side), 3) CRFR1 antagonist Antalarmin (500 pmol/side), or 4) CRF + Antalarmin prior to undergoing a hyperinsulinemic hypoglycemic (2.8 mM) clamp. A second series of studies also incorporated an infusion of [3H]glucose to allow the calculation of glucose dynamics. In addition the effect of CRFR1 antagonism in the paraventricular nucleus (PVN) was studied. Activation of VMH CRFR1 increased, whereas inhibition of CRFR1 suppressed hypoglycemia-induced CRRs. Inhibition of VMH CRFR1 also increased peripheral glucose utilization and reduced endogenous glucose production during hypoglycemia, whereas VMH CRF reduced peripheral glucose utilization. In contrast CRFR1 inhibition in the PVN blunted corticosterone but not epinephrine or glucagon CRR to hypoglycemia. In contrast to CRFR2 activation, CRFR1 activation within the VMH amplifies CRRs to acute hypoglycemia. The balance between these two opposing CRFRs in this key glucose-sensing region may play an important role in determining the magnitude of CRRs to acute hypoglycemia.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Thuraisingham, R., E. VIllar, M. Varagunam und M. Yaqoob. „THE CREATININE REDUCTION RATIO BETWEEN DAYS ONE AND TWO (CRR2) IS AN EARLY INDEPENDENT PREDICTOR OF POOR LONG TERM RENAL GRAFT SURVIVAL“. Transplantation 86, Supplement (Juli 2008): 462. http://dx.doi.org/10.1097/01.tp.0000331326.58792.e0.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Curzytek, Katarzyna, und Monika Leśkiewicz. „Targeting the CCL2-CCR2 axis in depressive disorders“. Pharmacological Reports 73, Nr. 4 (24.05.2021): 1052–62. http://dx.doi.org/10.1007/s43440-021-00280-w.

Der volle Inhalt der Quelle
Annotation:
AbstractSince affective disorders are considered to be underlain by the immune system malfunction, an important role in their pathophysiology is assigned to the proinflammatory mediators. Recently, chemokines, the group of chemotactic cytokines, have become a focus for basic and clinical scientists in the context of the development and treatment of brain diseases. Among them, chemokine CCL2 and its main receptor CCR2 have become candidate mediators of abnormal brain-immune system dialogue in depression. Besides the chemotactic activity, the CCL2-CCR2 axis is involved in various neurobiological processes, neurogenesis, neurotransmission, neuroinflammation, neurodegeneration, as well as neuroregeneration. Given the range of immunomodulatory possibilities that the CCL2-CCR2 pair can exert on the nervous system, its proinflammatory properties were initially thought to be a major contributor to the development of depressive disorders. However, further research suggests that the malfunctions of the nervous system are rather associated with impaired homeostatic properties manifested by the CCL2-CCR2 dyad dysfunctions. This review aims to present literature data on the action of the CCL2-CCR2 axis in the central nervous system under physiological and pathological conditions, as well as the contribution of this ligand-receptor system to the processes underlying affective disorders. Additionally, this article draws attention to the importance of the CCL2-CRR2 pathway as a potential pharmacological target with antidepressant potential.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Hosono, Naoko, Mahfouz Reda, Bartlomiej P. Przychodzen, Chantana Polprasert, Latifa Zekri, Michael J. Clemente, Jamal Tazi et al. „Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53“. Blood 124, Nr. 21 (06.12.2014): 784. http://dx.doi.org/10.1182/blood.v124.21.784.784.

Der volle Inhalt der Quelle
Annotation:
Abstract Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common chromosomal abnormality in MDS. The extent of individual defects vary, which may account for observed clinical diversity. Del(5q) pathogenesis has been related to haploinsufficiency of genes contained in the common deleted regions (CDR), including RPS14, miR-145/146a and SPARC. Driver mutations or pathogenic microdeletions were not identified for these genes, suggesting that multiple genes must function in combination to promote clonal evolution and phenotypic heterogeneity. Hence, we performed a comprehensive analysis of somatic mutations in genes located on chromosome 5 (chr5), both in patients with diploid 5q and in those with del(5q), to clarify the role of germline and somatic mutations in disease pathogenesis. In parallel, expression analysis was performed to correlate haploinsufficiency with the frequency of mutational events, in particular for diploid 5q cases. Applying SNP-array karyotyping to samples from 146 patients with del(5q), the lesion was identified in 5q31.1q33.1. Two retained regions (CRRs) were also observed in q11.1q14.2 (CRR1) and q34qter (CRR2). Lower-risk MDS is frequently affected by CDR, while in higher-risk MDS and secondary AML CRR1/2 are commonly co-involved. Using whole exome sequencing, we identified 11 hemizygous mutations located within the deleted area in del(5q) (N=59), while in cases diploid for 5q (N=330), 243 heterozygous mutations were found. One of the mutations discovered on chr5q afflicted a gene G3BP1 (5q33.1), located within the CDR and present in 2 patients. Both were missense mutations (one heterozygous and the other homo/hemizygous). A mutant case showed good responses to lenalidomide even though diploid 5. In addition, other somatic mutations of driver genes including TET2, CUX1 and EZH2 were concomitantly observed. Whole transcriptome sequencing demonstrated hemizygous loss of G3BP1 resulting in haploinsufficiency. G3BP1 was haploinsufficient in 48% of RAEB as well as low-risk MDS cases with del(5q). Overall, defective G3BP1 is associated with shorter overall survival (P<.001) in AML, consistent with the reports that del(5q) is a worse prognostic factor in myeloid neoplasms with aggressive phenotype. G3BP1 is a nuclear RNA-binding protein and is ubiquitously expressed in bone marrow, CD34+ progenitors and leukemic cell lines. Furthermore, G3BP1 binds to TP53 and its expression leads to the redistribution of TP53 from the nucleus to the cytoplasm. Similar to RPS14, haploinsufficient of G3BP1 resulted in TP53 up-modulation. Moreover, low expression of G3BP1 in diploid 5q cases was indeed associated with higher TP53 expression. Next, we generated haploinsufficient G3BP1 cell lines using shRNA transduction. Decreased expression of G3BP1 led to growth inhibition and impaired colony formation by transduced cells lines and hematopoietic progenitor cells, respectively. Knockdown of G3BP1 in K562 cell line increased TP53 in the nucleus, and when treated with CPT11, DNA-damaged induced G1-arrest was more prominent in knockdown cells. Furthermore, after knockdown of G3BP1 in TP53-null HL60 cells, we observed increased aneuploidy, suggesting that the loss of function of G3BP1 and TP53 may result in chromosomal instability. Most significantly, G3bp1-/+ mice showed lower blood counts and defective, dysplastic hematopoiesis, similar to lower-risk MDS. As previously described, TP53 defects are associated with advanced disease but recently it became apparent that TP53 may be one of the most common somatic lesions found in the context of del(5q). We stipulate that loss of TP53 function might overcome TP53 tumor suppressor effects and induce leukemic evolution in the defective G3BP1 status. In our cohort, TP53 mutations were more frequently present in high-risk phenotype with G3BP1 haploinsufficient expression. In conclusion, novel somatic mutations of G3BP1 suggest that it could be a candidate gene associated with the clonal evolution of del(5q). Loss of function or low expression of G3BP1 has been shown to up-modulate TP53 and result in dysplasia and growth inhibition, hallmarks of early stages of MDS. Additional events constitute loss of function of TP53, resulting in chromosomal instability, which is associated with leukemogenesis. Disclosures Sekeres: Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen Corp: Membership on an entity's Board of Directors or advisory committees; Boehringer-Ingelheim Corp: Membership on an entity's Board of Directors or advisory committees.
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dissertationen zum Thema "CRR2"

1

Blömacher, Margit [Verfasser]. „Characterization of mammalian CRN5 and CRN2 / Margit Blömacher“. Köln : Deutsche Zentralbibliothek für Medizin, 2013. http://d-nb.info/1052418589/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Fredriksson, Anna, und Sebastian Sporrong. „Intensivvårdssjuksköterskans vårdande av patienter med kontinuerlig njurersättningsterapi : En observationsstudie“. Thesis, Högskolan i Borås, Akademin för vård, arbetsliv och välfärd, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:hb:diva-9410.

Der volle Inhalt der Quelle
Annotation:
Continuous Renal Replacement Therapy, CRRT, är idag den behandling som oftast används inom intensivvården hos patienter i behov av dialys. Ett ökande antal studier genomförs för att förbättra CRRT behandlingen för patienten, men få studier belyser intensivvårdssjuksköterskans vårdande när det gäller skötsel och att upprätthålla CRRT. Syftet med denna studie är att beskriva aspekter av betydelse för intensivvårdssjuksköterskans vårdande av patienter i behov av kontinuerlig dialys på en intensivvårdsavdelning och för att besvara syftet ligger en kvalitativ ansats till grund för uppsatsen. Som datainsamlingsmetod valdes en ostrukturerad deltagande observation. Resultatet utmynnade i tre olika kategorier. I Vårdmiljö, beskrivs hur dialysmaskinen tar upp en stor del av rummet samt avger oljud när den larmar vilket kan upplevas stressande för både sjuksköterska och patient. I Organisation och åtgärd, beskrivs hur intensivvårdssjuksköterskan organiserar och planerar sina omvårdnadsåtgärder för att effektivisera arbetet samt säkerställa att patienten får en fullgod dialysbehandling utan längre uppehåll. I Omvårdnad och information visas att intensivvårdssjuksköterskor, som vårdar patienter i CRRT, fokuserar både på patient och teknik. När den kontinuerliga dialysen inte fungerar som planerat ökas stressen och fokus riskerar att flyttas från patienten till tekniken. CRRT ställer krav på intensivvårdssjuksköterskan, organisation och medarbetarna. Resultatet skulle kunna bidra till en ökad medvetenhet kring de utmaningar som intensivvårdssjuksköterskan ställs inför vid vård av patienter med CRRT.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Dreßen, Jochen. „Epitaxie und Charakterisierung oxidischer Schichtsysteme: BiSrCaCuO-Hochtemperatursupraleiter und ferromagnetisches CrO2“. Aachen : Shaker, 1999. http://deposit.d-nb.de/cgi-bin/dokserv?idn=970716621.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Brugel, D. „Theoretical studies of Cr2+(2) GaAs spectra“. Thesis, University of Nottingham, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.303719.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Ambrosino, Mariacarmela <1978&gt. „Ottimizzazione di un protocollo di anticoagulazione regionale con citrato in CRRT“. Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2014. http://amsdottorato.unibo.it/6516/.

Der volle Inhalt der Quelle
Annotation:
Ottimizzazione di un protocollo di anticoagulazione regionale con citrato in CRRT Introduzione: La necessità di un'anticoagulazione continua e l'ipofosforemia in corso di trattamento sono problemi costranti in corso di CRRT. Il nostro studio ha cercato di dimostrare l'efficacia e la sicurezza dell'anticoagulazione regionale con citrato in CVVH basato sull'utilizzo di una soluzione di citrato (18 mmol/L) associata ad una soluzione di reinfusione contenente fosfato, recentemente disponibile in commercio, al fine di ridurre l'ipofosfatemia in corso di CRRT. Metodi: Abbiamo utilizzato il nostro protocollo basato sull'utilizzo di una concentrazione di citrato contenente 18 mmol/l associata ad una soluzione di reinfusione contenente fosfato in un piccolo gruppo di pazienti ricoverati in terapia intensiva post-cardiochirurgica, sottoposti a CRRT per insufficienza renale acuta. Risultati: Il nostro protocollo ha garantito un'adeguata durata del circuito ed un ottimo controllo dell'equilibrio acido-base in ogni paziente. E' stata necessaria solo una minima supplementazione di fosforo in alcuni dei pazienti trattati. Conclusioni: Il nostro protocollo basato sull' utilizzo di una soluzione a concentrazione di citrato maggiore (18 mmol/l), permette un miglior controllo dell'equilibrio acido-base rispetto all'utilizzo della soluzione a più bassa concentrazione di citrato. L'uso di una minore dose di citrato ed il mantenimento di un target maggiore di calcio ionizzato all'interno del circuito sono comunque associati ad un'adeguata durata del circuito. I livelli di fosforemia sono rimasti sostanzialmente stabili nella maggior parte dei pazienti trattati, grazie alla presenza di fosfato nella soluzione utilizzata come reinfusione in post-diluizione.
Optimization of a regional citrate anticoagulation protocol in CRRT Purpose: Prolonged anticoagulation and hypophosphatemia are well known drawbacks of CRRT. The aim of our study was to show the efficacy and safety of a regional citrate anticoagulation protocol for CVVH combined with a phosphate containing replacement fluid. Methods: We used our protocol, based on a citrate solution (18 mmol/l) combined with in a phosphate containing replacement fluid, in a small cohort of heart surgery patients. Results: Our protocol provided an adequate circuit lifetime and an excellent acid-base status in every patient. A low amount of phosphorus supplememntation was required only in a very few patients. Conclusions: Our protocol based on a citrate solution (18 mmol/l) combined with a phosphate containing replacement fluid, allows a better buffer balance control than using of a lower citrate solution. Moreover, an adequate circuit lifetime was obtained. Serum phosphate was steadily maintained in all patients. Only in a very few patients a low supplementation was required.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Schütte, Mark [Verfasser], und Stefan [Akademischer Betreuer] Dübel. „Crf2 - Ein neues Antigen von Aspergillus fumigatus / Mark Schütte ; Betreuer: Stefan Dübel“. Braunschweig : Technische Universität Braunschweig, 2009. http://d-nb.info/1175829587/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Dreßen, Jochen [Verfasser]. „Epitaxie und Charakterisierung oxidischer Schichtsysteme: BiSrCaCuO-Hochtemperatursupraleiter und ferromagnetisches CrO2 / Jochen Dreßen“. Aachen : Shaker, 1999. http://d-nb.info/970716621/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Momozawa, Ai [Verfasser]. „Precipitation and Microstractural Change Mechanism in TiB2-W2B5-CrB2 Ceramics / Ai Momozawa“. Aachen : Shaker, 2007. http://d-nb.info/1164341049/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Shek, Ka-wai. „DNASE2, CR2, TYK2 genes polymorphisms in systemic lupus erythematosus /“. View the Table of Contents & Abstract, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38278765.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Shek, Ka-wai, und 石家偉. „DNASE2, CR2, TYK2 genes polymorphisms in systemic lupus erythematosus“. Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B45012945.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bücher zum Thema "CRR2"

1

Connecticut. General Assembly. Legislative Program Review and Investigations Committee. CRRA and other quasi-public agencies. Hartford: Connecticut General Assembly, Legislative Program Review and Investigations Committee, 2002.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

[Mentor, Darlyn]. CRRF facts about-- racism in our schools. [Toronto]: Canadian Race Relations Foundation = Fondation canadienne des relations raciales, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Cairney, Trevor. Investigating ICT capacity in the Hunter and Central Coast Regions: A research report by CRRI. Sydney: Centre for Regional Research and Innovation, 2002.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Caviezel, Fidel. La CRR dapi la fundaziun 1946 tochen 1996: Il svilup dalla CRR e dallas emissiuns romontschas da radio e televisiun da 1946-1996, cun ina cuorta egliada el futur. Cuera: CRR, 1996.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Czech Republic) Conference on the Rehabilitation and Reconstruction of Buildings (14th 2012 Brno. Proceedings of the Conference on the Rehabilitation and Reconstruction of Buildings, CRRB 2012: Selected, peer reviewed papers from the Conference on the Rehabilitation and Reconstruction of Buildings 2012 (CRRB 2012), November 6-7, 2012, Brno, Czech Republic. Durnten-Zurich: Trans Tech Publications Ltd., 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Punka, George. Fiat CR32/CR42 in action. Squadron/Signal Publications, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Luz, Günther, Werner Neus, Mathias Schaber, Peter Schneider, Claus-Peter Wagner und Max Weber, Hrsg. CRR visuell. Schäffer-Poeschel, 2020. http://dx.doi.org/10.34156/9783791043173.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Luz, Günther, Werner Neus, Mathias Schaber, Peter Schneider, Claus-Peter Wagner und Max Weber, Hrsg. KWG und CRR. Schäffer-Poeschel, 2018. http://dx.doi.org/10.34156/9783791037899.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Gladiator Vs Cr42 Falco 194041. Osprey Publishing (UK), 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

CRRI perspective plan: Vision - 2025. Cuttack: Central Rice Research Institute, Indian Council of Agricultural Research, 2007.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "CRR2"

1

Posypaiko, V. I., und E. A. Alekseeva. „CrF2“. In Phase Equilibria in Binary Halides, 117. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-9024-4_36.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Assadi, Farahnak, und Fatemeh Ghane Sharbaf. „CRRT Prescription“. In Pediatric Continuous Renal Replacement Therapy, 71–97. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-26202-4_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Ricci, Zaccaria, und Stuart L. Goldstein. „Pediatric CRRT“. In Acute Nephrology for the Critical Care Physician, 255–61. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17389-4_20.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Mufwene, Salikoko S. „Creoles and creolization“. In Handbook of Pragmatics, 1–14. Amsterdam: John Benjamins Publishing Company, 1996. http://dx.doi.org/10.1075/hop.1.cre2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Mufwene, Salikoko S. „Creoles and creolization“. In Handbook of Pragmatics, 1–17. Amsterdam: John Benjamins Publishing Company, 2007. http://dx.doi.org/10.1075/hop.11.cre2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Brophy, Patrick, Irfan Khan und Akash Deep. „Anticoagulation in CRRT“. In Critical Care Nephrology and Renal Replacement Therapy in Children, 251–69. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90281-4_17.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Mottes, Theresa A. „CRRT Program Development“. In Critical Care Nephrology and Renal Replacement Therapy in Children, 357–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90281-4_23.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Assadi, Farahnak, und Fatemeh Ghane Sharbaf. „Pharmacokinetics of CRRT“. In Pediatric Continuous Renal Replacement Therapy, 99–120. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-26202-4_5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Suski, W., und T. Palewski. „(Gd1.16□0.11S1.27)CrS2“. In Pnictides and Chalcogenides II, 647–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/10713485_174.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Rogiers, P. „Update on CRRT Therapy“. In Anesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E., 499–506. Milano: Springer Milan, 2000. http://dx.doi.org/10.1007/978-88-470-2286-7_53.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "CRR2"

1

Takeda, Katsuyuki, Joshua M. Thurman, Stephen Tomlinson, Masakazu Okamoto, Yoshiki Shiraishi, V. M. Holers und Erwin W. Gelfand. „Intratracheal Administration Of The Complement-Inhibitory Proteins CR2-Crry And CR2-fH Modulate Allergen-Induced Airway Hyperresponsiveness (AHR) And Inflammation“. In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2831.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Santhanakrishnan, Arvind, Trent Nestle, Brian Moore, Ajit P. Yoganathan und Matthew L. Paden. „Characterization of a Low Extracorporeal Volume, High Accuracy Pediatric Continuous Renal Replacement Therapy Device“. In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80210.

Der volle Inhalt der Quelle
Annotation:
The incidence of acute kidney injury (AKI) is commonly seen in critically ill children, the origins of which may be traced to a wide range of conditions such as inborn errors of metabolism, sepsis, congenital heart defects, bone marrow and organ transplantation, and to a lesser extent from multiple organ dysfunction syndrome (MODS) [1]. It is vital to provide a form of fluid and electrolyte clearance in these patients until native renal function improves. Nearly 3,600 critically ill children per year with acute kidney injury receive life-saving continuous renal replacement therapy (CRRT) in the United States. However, there is no CRRT device approved by the Food and Drug Administration for use in pediatric patients. Thus, clinicians unsafely adapt adult CRRT devices for use in the pediatric patients due to lack of safer alternatives. Complications observed with using adult adapted CRRT devices in children include hypotension, hemorrhage, thrombosis, temperature instability, inaccurate fluid balance between ultrafiltrate (UF) removed from and replacement fluid (RF) delivered to the patient, electrolyte disorders, and alteration of drug clearance. This research addresses this unmet clinical need through the design, mechanical and biological characterization of a pediatric specific Kidney Injury and Dysfunction Support (KIDS) CRRT device that provides high accuracy in fluid balance, reduces extracorporeal blood volume, and eliminates other problems associated with using adapted adult CRRT devices in children.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Li, Xinpeng, und Sheng Fang. „Assessment of Control Room Radiological Habitability of High-Temperature Reactor Pebble-Bed Module in Shidao Bay Multi-Reactor Nuclear Power Site“. In 2018 26th International Conference on Nuclear Engineering. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/icone26-82448.

Der volle Inhalt der Quelle
Annotation:
The control room radiological habitability (CRRH) is important for staff safety in a nuclear power plant, which is also a licensing requirement of the High-temperature Reactor Pebble-bed Module (HTR-PM) in China. Meanwhile, the complexity of the dose assessment increases for the multi-reactor site, which put forward higher requirements for building layout. The CRRH is investigated comprehensively for the multi-reactor site at Shidao Bay in this study. For a large-break loss of coolant accident of HTR-PM and CAP1000 in Shidao Bay nuclear power site, this study estimates doses of body, thyroid and skin due to three exposure pathways using NRC-recommended ARCON96 and dose calculation method in RG 1.195. To perform a realistic evaluation, the latest design and site-specific information are utilized as the input parameters, including the unique accidental source term of HTR-PM and the RG1.183-recommended source term of CAP1000, the release and ventilation parameters, the final layout and the meteorological data in a whole year. The evaluation results demonstrate that the individual dose level of staff in the control room is far below the requirement of the regulatory guide, which guarantees the CRRH of HTR-PM. The contribution of primary radionuclides suggests that tellurium and iodine are primary contributors of the inhalation dose of body and thyroid, which is worthy of paying particular attention to the CRRH design in HTR-PM.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Kueck, Stefan. „Cr2+lasers“. In International Conference on Lasers, Applications, and Technologies 2002 Advanced Lasers and Systems, herausgegeben von Guenter Huber, Ivan A. Scherbakov und Vladislav Y. Panchenko. SPIE, 2003. http://dx.doi.org/10.1117/12.517890.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Keizer, R. S., S. T. B. Goennenwein, I. van Dijk, T. M. Klapwijk und A. Gupta. „Planar Hall Effect In CrO2“. In LOW TEMPERATURE PHYSICS: 24th International Conference on Low Temperature Physics - LT24. AIP, 2006. http://dx.doi.org/10.1063/1.2355272.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Sorokina, Irina T., Evgeni Sorokin, Victor Shcherbitsky, Nikolai V. Kuleshov, Guohua Zhu, A. Franz und M. A. Noginov. „Novel mid-infrared random power lasers: Cr2+:ZnS vs. Cr2+:ZnSe“. In International Quantum Electronics Conference. Washington, D.C.: OSA, 2004. http://dx.doi.org/10.1364/iqec.2004.ithg22.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Samarakoon, S. M. Samindi M. K., und R. M. Chandima Ratnayake. „On the Necessity for Minimizing Risk Based Technology Qualification Variability: An Application to Offshore Floating Wind Turbines“. In ASME 2020 39th International Conference on Ocean, Offshore and Arctic Engineering. American Society of Mechanical Engineers, 2020. http://dx.doi.org/10.1115/omae2020-18139.

Der volle Inhalt der Quelle
Annotation:
Abstract Technology qualification (TQ) has been employed to perform assessments to verify whether a new technology performs within pre-specified functional limits after an application. If a best available technology (BAT) is used in a new environment, it is considered as a new technology. The TQ is vital in the implementation of best available technology (BAT) in a new environment. Risk based technology qualification provides an optimal approach for performing TQ of a BAT when it is necessary to implement in a new environment. This manuscript first demonstrates the standard TQ process. Secondly, it presents development of a risk matrix for failure mode identification and consequence risk ranking (FMI&CRR). Thirdly, it demonstrates the use of FMI&CRR in a risk-based technology qualification process. Finally, it presents use of the risk matrix to perform TQ on moorings solutions that have been selected as a BAT for a floating wind turbine sub-system. Fuzzy inference system has been used to assess the risk rank to minimize the variability that causes due to experts’ performance variability. Illustrative risk based TQ assessment has been performed and presented. The developed risk based TQ process (TQP), fuzzy inference system supported risk rank estimation, and illustrative risk based TQ recommendation are significantly important for practitioners while performing FMI&CRR in larger scale offshore floating wind turbines’ TQ projects.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Aro, Stephen C., Justin R. Sparks, Sean A. McDaniel, Michael G. Coco, Alex T. Hendrickson, Venkatraman Gopalan, Gary Cook und John V. Badding. „Cr2+:ZnSe Fiber Lasers“. In Advanced Solid State Lasers. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/assl.2016.aw3a.4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Sorokina, Irina T., und Evgeni Sorokin. „Sensitization of the induced radiation in Cr2+:ZnSe and Cr2+:ZnS lasers“. In Nonlinear Optics: Materials, Fundamentals and Applications. Washington, D.C.: OSA, 2002. http://dx.doi.org/10.1364/nlo.2002.wb7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Kim, C., D. V. Martyshkin, V. V. Fedorov und S. B. Mirov. „Room-temperature mid-infrared Cr2+:ZnSe and Cr2+:ZnS random powder lasers“. In Lasers and Applications in Science and Engineering, herausgegeben von W. Andrew Clarkson, Norman Hodgson und Ramesh K. Shori. SPIE, 2008. http://dx.doi.org/10.1117/12.764176.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "CRR2"

1

Schepler, Kenneth L., Jason B. McKay und Won B. Roh. Extended Mid-Infrared (IR) Tuning of a Cr2+:CdSe Lasers. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2001. http://dx.doi.org/10.21236/ada400505.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie